Primary cutaneous follicle centre lymphoma natural history, complications and prognosis: Difference between revisions
(Created page with "__NOTOC__ {{Primary cutaneous follicle centre lymphoma}} Please help WikiDoc by adding content here. It's easy! Click here to learn about edit...") |
|||
(13 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Primary cutaneous follicle centre lymphoma}} | {{Primary cutaneous follicle centre lymphoma}} | ||
{{CMG}}; {{AE}} {{AS}} | |||
==Overview== | |||
Prognosis is generally excellent, and the 5-year survival rate of patients with primary cutaneous follicle centre lymphoma is approximately 97%. | |||
==Natural History== | |||
* Primary cutaneous follicle centre lymphoma shows a predilection for the scalp, forehead, and trunk and dissemination to extracutaneous sites rarely occurs.<ref name="hindawi"> Transformation of a Cutaneous Follicle Center Lymphoma to a Diffuse Large B-Cell Lymphoma—An Unusual Presentation. Hindawi. http://www.hindawi.com/journals/crim/2010/296523/. Accessed on March 02, 2016</ref> | |||
* Cutaneous [[relapses]] noted in ~30% of patients.<ref name="cancer.gov"> Primary cutaneous follicle centre lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf5ae3e27c3994bd549b/. Accessed on March 02, 2016</ref> | |||
* [[Recurrences]] usually proximate to the initial site of the tumor. | |||
* Untreated skin lesions increase in size, rarely [[metastases]] to other sites. | |||
==Complications== | |||
* Transformation of systemic follicular lymphoma (FL) into aggressive non-Hodgkin's lymphoma is associated with poor prognosis and has been reported with a wide range of frequency (range between 10%–70%). | |||
* While the annual risk of transformation of systemic follicular lymphoma (FL) is 3%. | |||
==Prognosis== | |||
* Prognosis is generally excellent, and the 5-year survival rate of patients with primary cutaneous follicle centre lymphoma is approximately 97%. | |||
* The International Extranodal Lymphoma Study Group identified three prognostic factors, that are used to assess a cutaneous lymphoma international prognostic index (CLIPI), which is [[prognosis|prognostic]] of disease-free status.<ref name="Wilcox2015">{{cite journal |authors=Wilcox RA |title=Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management |journal=Am. J. Hematol. |volume=90 |issue=1 |pages=73–6 |year=2015 |pmid=25535037 |doi=10.1002/ajh.23863 |url=}}</ref> | |||
:* Elevated [[Lactate dehydrogenase|LDH]] | |||
:* More than two skin lesions | |||
:* Nodular lesions | |||
* If left untreated, the lesions typically increase in size over years. | |||
* In approximately 10 percent of patients may disseminate to extracutaneous sites.<br /> | |||
==References== | ==References== | ||
Line 9: | Line 28: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category: | [[Category:Oncology]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Latest revision as of 16:12, 29 October 2019
Primary cutaneous follicle centre lymphoma Microchapters |
Differentiating Primary cutaneous follicle centre lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Primary cutaneous follicle centre lymphoma natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Primary cutaneous follicle centre lymphoma natural history, complications and prognosis |
FDA on Primary cutaneous follicle centre lymphoma natural history, complications and prognosis |
CDC on Primary cutaneous follicle centre lymphoma natural history, complications and prognosis |
Primary cutaneous follicle centre lymphoma natural history, complications and prognosis in the news |
Blogs on Primary cutaneous follicle centre lymphoma natural history, complications and prognosis |
Directions to Hospitals Treating Splenic marginal zone lymphoma |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Prognosis is generally excellent, and the 5-year survival rate of patients with primary cutaneous follicle centre lymphoma is approximately 97%.
Natural History
- Primary cutaneous follicle centre lymphoma shows a predilection for the scalp, forehead, and trunk and dissemination to extracutaneous sites rarely occurs.[1]
- Cutaneous relapses noted in ~30% of patients.[2]
- Recurrences usually proximate to the initial site of the tumor.
- Untreated skin lesions increase in size, rarely metastases to other sites.
Complications
- Transformation of systemic follicular lymphoma (FL) into aggressive non-Hodgkin's lymphoma is associated with poor prognosis and has been reported with a wide range of frequency (range between 10%–70%).
- While the annual risk of transformation of systemic follicular lymphoma (FL) is 3%.
Prognosis
- Prognosis is generally excellent, and the 5-year survival rate of patients with primary cutaneous follicle centre lymphoma is approximately 97%.
- The International Extranodal Lymphoma Study Group identified three prognostic factors, that are used to assess a cutaneous lymphoma international prognostic index (CLIPI), which is prognostic of disease-free status.[3]
- Elevated LDH
- More than two skin lesions
- Nodular lesions
- If left untreated, the lesions typically increase in size over years.
- In approximately 10 percent of patients may disseminate to extracutaneous sites.
References
- ↑ Transformation of a Cutaneous Follicle Center Lymphoma to a Diffuse Large B-Cell Lymphoma—An Unusual Presentation. Hindawi. http://www.hindawi.com/journals/crim/2010/296523/. Accessed on March 02, 2016
- ↑ Primary cutaneous follicle centre lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf5ae3e27c3994bd549b/. Accessed on March 02, 2016
- ↑ Wilcox RA (2015). "Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management". Am. J. Hematol. 90 (1): 73–6. doi:10.1002/ajh.23863. PMID 25535037.